Literature DB >> 17262179

Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling.

E Beristain1, C Martínez-Bouzas, I Guerra, N Viguera, J Moreno, E Ibañez, J Díez, F Rodríguez, G Mallabiabarrena, S Luján, J Gorostiaga, J L De Pablo, J L Mendizabal, M I Tejada.   

Abstract

The prevalence of unique and recurrent BRCA1 and BRCA2 pathogenic mutations and unclassified variants varies among different populations. Two hundred and thirty-six breast and/or ovarian cancer patients were analysed to clarify the role of these genes in the Basque Country. We also studied 130 healthy women from the general population from the same region. Fifteen different pathological mutations were found in 16 index cases: 10 truncating mutations, 4 missense mutations and 1 splicing mutation. c.3002_3003insT and c.5788_5789delGT, both in exon 11 of BRCA2 have not previously been described. No pathological mutations were found in cases of sporadic juvenile breast cancer. There are no recurrent mutations in our population; apart from the mutation c.9254_9258del5, which appears in only two index cases. We have also found a lot of variants whose effect is unknown. From these variants, 17 have not previously been described: 6 missenses, 6 synonymous and 5 alterations in intronic regions. We would like to highlight the fact that 14.3% of patients with 3 or more cases of breast cancer in the family, and 16.7% of patients with family history of breast and ovarian cancer, present a pathological mutation in BRCA1 or BRCA2. This manuscript demonstrates that each population can have different mutations and due to this, Genetic Counselling and selection criteria must be different for each population. Furthermore, this article describes for the first time some new mutations and unclassified variants found in our population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17262179     DOI: 10.1007/s10549-006-9489-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  15 in total

1.  LOH analysis should not be used as a tool to assess whether UVs of BRCA1/2 are pathogenic or not.

Authors:  E Beristain; I Guerra; N Vidaurrazaga; J Burgos-Bretones; M I Tejada
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

2.  Heterogeneous prevalence of recurrent BRCA1 and BRCA2 mutations in Spain according to the geographical area: implications for genetic testing.

Authors:  Orland Diez; Sara Gutiérrez-Enríquez; Judith Balmaña
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

3.  Breast and ovarian cancer risk evaluation in families with a disease-causing mutation in BRCA1/2.

Authors:  Elena Beristain; Berta Ibáñez; Itziar Vergara; Cristina Martínez-Bouzas; Isabel Guerra; Maria Isabel Tejada
Journal:  J Community Genet       Date:  2010-08-09

4.  Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families.

Authors:  Emily P Slater; Peter Langer; Volker Fendrich; Nils Habbe; Brunhilde Chaloupka; Elvira Matthäi; Mercedes Sina; Stephan A Hahn; Detlef K Bartsch
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

5.  Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence.

Authors:  Inmaculada de Juan Jiménez; Zaida García Casado; Sarai Palanca Suela; Eva Esteban Cardeñosa; José Antonio López Guerrero; Ángel Segura Huerta; Isabel Chirivella González; Ana Beatriz Sánchez Heras; Ma José Juan Fita; Isabel Tena García; Carmen Guillen Ponce; Eduardo Martínez de Dueñas; Ignacio Romero Noguera; Dolores Salas Trejo; Mercedes Goicoechea Sáez; Pascual Bolufer Gilabert
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

6.  Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort.

Authors:  Ava Kwong; Connie H N Wong; Dacita T K Suen; Michael Co; Allison W Kurian; Dee W West; James M Ford
Journal:  World J Surg       Date:  2012-04       Impact factor: 3.352

Review 7.  BRCA-associated ovarian cancer: from molecular genetics to risk management.

Authors:  Giulia Girolimetti; Anna Myriam Perrone; Donatella Santini; Elena Barbieri; Flora Guerra; Simona Ferrari; Claudio Zamagni; Pierandrea De Iaco; Giuseppe Gasparre; Daniela Turchetti
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

8.  Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain).

Authors:  Pilar Blay; Iñigo Santamaría; Ana S Pitiot; María Luque; Marta G Alvarado; Ana Lastra; Yolanda Fernández; Angeles Paredes; José M P Freije; Milagros Balbín
Journal:  BMC Cancer       Date:  2013-05-17       Impact factor: 4.430

9.  CDKL5 gene status in female patients with epilepsy and Rett-like features: two new mutations in the catalytic domain.

Authors:  Hiart Maortua; Cristina Martínez-Bouzas; María-Teresa Calvo; Maria-Rosario Domingo; Feliciano Ramos; Ainhoa García-Ribes; María-Jesús Martínez; María-Asunción López-Aríztegui; Nerea Puente; Izaskun Rubio; María-Isabel Tejada
Journal:  BMC Med Genet       Date:  2012-08-06       Impact factor: 2.103

10.  Functional characterization of BRCA1 gene variants by mini-gene splicing assay.

Authors:  Ane Y Steffensen; Mette Dandanell; Lars Jønson; Bent Ejlertsen; Anne-Marie Gerdes; Finn C Nielsen; Thomas vO Hansen
Journal:  Eur J Hum Genet       Date:  2014-03-26       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.